The price of VYNE Therapeutics Inc. (NASDAQ:VYNE) shares last traded on Wall Street fell -1.48% to $0.27.
Based on available information, 4 analysts follow VYNE Therapeutics Inc. (NASDAQ:VYNE). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $1.50, we find $4.00. Given the previous closing price of $0.27, this indicates a potential upside of 1381.48 percent. VYNE stock price is now 3.28% away from the 50-day moving average and -37.63% away from the 200-day moving average. The market capitalization of the company currently stands at $14.28M.
Among analysts, 1 rate the stock a hold while 3 rate it a buy. Brokers who have rated the stock have averaged $3.50 as their price target over the next twelve months.
In other news, LEPORE PATRICK G, Director bought 12,500 shares of the company’s stock on Nov 30. The stock was bought for $12,699 at an average price of $1.02. Upon completion of the transaction, the Director now directly owns 62,500 shares in the company, valued at $16875.0. Insiders disposed of 70,022 shares of company stock worth roughly $18905.940000000002 over the past 1 year. A total of 2.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VYNE stock. A new stake in VYNE Therapeutics Inc. shares was purchased by CITADEL ADVISORS LLC during the first quarter worth $23,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP invested $7,000 in shares of VYNE during the first quarter. In the first quarter, MARINER, LLC acquired a new stake in VYNE Therapeutics Inc. valued at approximately $4,000. In total, there are 55 active investors with 17.00% ownership of the company’s stock.
A candlestick chart of VYNE Therapeutics Inc. (NASDAQ: VYNE) showed a price of $0.2500 on Monday morning. During the past 12 months, VYNE Therapeutics Inc. has had a low of $0.22 and a high of $1.75. The fifty day moving average price for VYNE is $0.2575 and a two-hundred day moving average price translates $0.4264 for the stock.
The latest earnings results from VYNE Therapeutics Inc. (NASDAQ: VYNE) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.15, beating analysts’ expectations of -$0.17 by 0.02. This compares to -$0.18 EPS in the same period last year. The company reported revenue of $0.13 million for the quarter, compared to $0.29 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -57.29 percent. For the current quarter, analysts expect VYNE to generate $130k in revenue.
VYNE Therapeutics Inc.(VYNE) Company Profile
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.